Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04338074 · ClinicalTrials.gov registry record · Phase 2
TXA and Corona Virus 2019 (COVID19) in Outpatients
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT04338074 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 5 participants.
The verdict
NCT04338074, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
Interventions
- DRUG Placebo oral tablet
- DRUG Tranexamic acid tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2021-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04338074
The ClinicalTrials.gov registry entry for NCT04338074 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo oral tablet is the first listed.
NCT04338074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04338074 about?
NCT04338074 is a clinical study titled "TXA and Corona Virus 2019 (COVID19) in Outpatients". A controlled trial of the drug tranexamic acid (TXA) in outpatients who were recently diagnosed with COVID-19. It is hypothesized that TXA will reduce the infectivity and virulence of the virus.
What is the current status of trial NCT04338074?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-06-01. Estimated completion is 2021-04-21.
What interventions are being tested in trial NCT04338074?
The interventions under investigation include: Placebo oral tablet (DRUG), Tranexamic acid tablets (DRUG).
Who is sponsoring clinical trial NCT04338074?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.